Literature DB >> 30125871

Psychosis and synthetic cannabinoids.

Huiqiong Deng1, Christopher D Verrico2, Thomas R Kosten2, David A Nielsen2.   

Abstract

Synthetic cannabinoid (SC) products have gained popularity as abused drugs over the past decade in many countries. The SCs broadly impact psychological state (e.g., mood, suicidal thoughts and psychosis) and physiological functions (e.g., cardiovascular, gastrointestinal and urinary). This review is about the effects of SCs on psychotic symptoms in clinical settings and the potentially relevant chemistry and mechanisms of action for SCs. Induction of psychotic symptoms after consuming SC products were reported, including new-onset psychosis and psychotic relapses. The role of SCs in psychosis is more complex than any single chemical component might explain, and these effects may not be a simple extension of the typical effects of cannabis or natural cannabinoids.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Cannabinoids; Cannabis; K2; Psychoactive substances; Psychosis; Spice; Synthetic cannabinoids

Mesh:

Substances:

Year:  2018        PMID: 30125871     DOI: 10.1016/j.psychres.2018.08.012

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  11 in total

Review 1.  Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.

Authors:  Eun Yong Chung; Hye Jin Cha; Hyun Kyu Min; Jaesuk Yun
Journal:  Arch Pharm Res       Date:  2021-04-02       Impact factor: 4.946

2.  Use of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005-2017.

Authors:  Joseph J Palamar; Austin Le
Journal:  Hum Psychopharmacol       Date:  2019-03-06       Impact factor: 1.672

Review 3.  The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective.

Authors:  Laura Orsolini; Stefania Chiappini; Duccio Papanti; Domenico De Berardis; John M Corkery; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2019-11-20       Impact factor: 4.157

4.  The Changing Landscape of Substance Use Disorders.

Authors: 
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-04-10

5.  In Vivo Bio-Activation of JWH-175 to JWH-018: Pharmacodynamic and Pharmacokinetic Studies in Mice.

Authors:  Micaela Tirri; Raffaella Arfè; Sabrine Bilel; Giorgia Corli; Beatrice Marchetti; Anna Fantinati; Fabrizio Vincenzi; Fabio De-Giorgio; Cristian Camuto; Monica Mazzarino; Mario Barbieri; Rosa Maria Gaudio; Katia Varani; Pier Andrea Borea; Francesco Botrè; Matteo Marti
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

Review 6.  Review of the Endocannabinoid System.

Authors:  Hui-Chen Lu; Ken Mackie
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2020-08-01

Review 7.  Cannabis and Psychosis Through the Lens of DSM-5.

Authors:  Nathan T Pearson; James H Berry
Journal:  Int J Environ Res Public Health       Date:  2019-10-28       Impact factor: 3.390

Review 8.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

9.  Cannabis health knowledge and risk perceptions among Canadian youth and young adults.

Authors:  Cesar Leos-Toro; Geoffrey T Fong; Samantha B Meyer; David Hammond
Journal:  Harm Reduct J       Date:  2020-08-03

10.  Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity.

Authors:  Marilisa P Dimmito; Azzurra Stefanucci; Stefano Pieretti; Paola Minosi; Szabolcs Dvorácskó; Csaba Tömböly; Gokhan Zengin; Adriano Mollica
Journal:  Biomolecules       Date:  2019-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.